Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

Description

CORAL GABLES, Fla., March 10, 2022 /PRNewswire/ — Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively. Please find additional details about the events below.

Relmada Therapeutics Corporate Logo (PRNewsFoto/Relmada Therapeutics, Inc.)

Needham & Company's 1st Annual Neuroscience Forum (virtual)
Date: Wednesday, March 16, 2022, 9:30-10:10am ET
Webcast: https://wsw.com/webcast/needham118/rlmd/2253300

Oppenheimer's 32nd Annual Healthcare Conference (virtual)
Date: Thursday, March 17, 2022, 1:20-1:50pm ET
Webcast: https://wsw.com/webcast/oppenheimer20/rlmd/2773890

The webcasts can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. Archived replays will be available for 90 days after the conclusion of the events.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic

neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact

Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

Media Inquiries

FischTank PR
relmada@fischtankpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-fireside-chats-at-two-upcoming-healthcare-events-301500047.html

SOURCE Relmada Therapeutics, Inc.

Released March 10, 2022

Date Created
2022/03/10